Gynecologic oncology最新文献

{"title":"Less is more: The benefits of reduced follow-up in gynecologic cancers","authors":"Julien A.M. Vos , M. Caroline Vos , Luc R.C.W. van Lonkhuijzen , Lonneke V. van de Poll-Franse , Nicole P.M. Ezendam","doi":"10.1016/j.ygyno.2024.12.008","DOIUrl":"10.1016/j.ygyno.2024.12.008","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages 178-180"},"PeriodicalIF":4.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living in a food desert in Louisiana and its effects on gynecologic cancer outcomes","authors":"Tina Nguyen MS ,&nbsp;Yong Yi PhD ,&nbsp;Shawna Morron PA-C ,&nbsp;Devin Brittain RD LDN ,&nbsp;Ryan Yates RD LDN ,&nbsp;Tara Castellano MD ,&nbsp;Amelia Jernigan MD ,&nbsp;Xiao-Cheng Wu MD MPH ,&nbsp;Navya Nair MD MPH","doi":"10.1016/j.ygyno.2024.12.001","DOIUrl":"10.1016/j.ygyno.2024.12.001","url":null,"abstract":"<div><h3>Objective</h3><div>Food insecurity is becoming recognized as an important measure of public health. Louisiana has a poorer health index and a higher food insecurity rate than the national average. This study aims to investigate how living in a food desert affects the stage at diagnosis and 5-year overall survival in patients with gynecologic cancers.</div></div><div><h3>Methods</h3><div>Data on genital cancers diagnosed between 2015 and 2019 among Louisiana women aged 20 years and older were from the Louisiana Tumor Registry. The food desert data was based on the USDA Food Access Research Atlas (FARA). The covariates included in this study were race, age, insurance status, BMI, tobacco use, and Charlson Comorbidity Index. Univariate, multivariable logistic regression and Cox proportional hazard regression models were employed.</div></div><div><h3>Results</h3><div>Food insecurity is independently associated with diagnoses at an advanced stage in patients with cervical and uterine cancer (OR = 1.41 [1.01, 1.96] and 1.28 [1.04, 1.58], respectively) after adjusting for covariates. This association was not observed in patients with ovarian cancer (OR = 0.94 [0.64, 1.39]). In evaluating overall survival at 5 years after initial diagnosis, patients living in a food desert have higher mortality rates across cervical, uterine, and ovarian cancers in the univariate analysis (OR = 1.27 [1.01, 1.60], 1.27 [1.07, 1.49], and 1.34 [1.10, 1.65], respectively); however, this significance is diminished in the multivariate analyses.</div></div><div><h3>Conclusions</h3><div>Food insecurity affects gynecologic cancer morbidity and can offer an important point of intervention to increase cancer prevention initiatives and improve resources for underserved populations.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages 137-144"},"PeriodicalIF":4.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical trials are not the solution to inequities in cancer care","authors":"David I. Shalowitz ,&nbsp;Franklin G. Miller","doi":"10.1016/j.ygyno.2025.01.004","DOIUrl":"10.1016/j.ygyno.2025.01.004","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages A1-A2"},"PeriodicalIF":4.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143038152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer","authors":"Stephen Graves ,&nbsp;Mackenzie W. Sullivan ,&nbsp;Anusha Adkoli ,&nbsp;Qin Zhou ,&nbsp;Alexia Iasonos ,&nbsp;Pier Selenica ,&nbsp;Carol Aghajanian ,&nbsp;Ying L. Liu ,&nbsp;William Tew ,&nbsp;Yukio Sonoda ,&nbsp;Lora H. Ellenson ,&nbsp;Dennis Chi ,&nbsp;Roisin E. O'Cearbhaill ,&nbsp;Britta Weigelt ,&nbsp;Rachel N. Grisham","doi":"10.1016/j.ygyno.2024.11.011","DOIUrl":"10.1016/j.ygyno.2024.11.011","url":null,"abstract":"<div><h3>Objective</h3><div>We sought to describe the association between genomic instability score (GIS) and progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed, non<em>-BRCA1/2</em> ovarian cancer.</div></div><div><h3>Methods</h3><div>Homologous recombinant deficiency (HRD) status was based on a cutoff of ≥42 GIS; patients &lt;42 were categorized with homologous recombination proficiency (HRP). We collected type and duration of maintenance therapy, among other variables, and built a multivariate model with landmark analysis at 6 months from baseline and applied it for time-dependent variables.</div></div><div><h3>Results</h3><div>Increasing GIS as a continuous variable was associated with improved PFS and OS in our cohort. Overall, median PFS was significantly longer in patients with HRD ovarian cancer (35.4 months, 25.4–NE) than in those with HRP disease (14.9 months, 13.1–16.2; <em>p</em> &lt; 0.001). Median OS was 36.2 months (32.4–NE) for HRP and not reached for HRD (<em>p</em> = 0.002). Notably, in patients with HRP ovarian cancer, we observed a shorter median PFS in those who received a poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) than in those who did not (12.7 months for HRP with PARPi vs 15.2 months for HRP without PARPi).</div></div><div><h3>Conclusions</h3><div>Our results demonstrate that in newly diagnosed advanced non-<em>BRCA1/2</em> ovarian cancer, GIS as a continuous variable is associated with longer PFS and OS. In patients with HRP ovarian cancer, PARPi treatment may be associated with shorter PFS, which warrants further evaluation.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages 120-127"},"PeriodicalIF":4.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis.","authors":"Emanuele Perrone, Ilaria Capasso, Diana Giannarelli, Rita Trozzi, Luigi Congedo, Elisa Ervas, Vincenzo Tarantino, Giovanni Esposito, Luca Palmieri, Arianna Guaita, Anne-Sophie van Rompuy, Giulia Scaglione, Gian Franco Zannoni, Giovanni Scambia, Frédéric Amant, Francesco Fanfani","doi":"10.1016/j.ygyno.2024.10.010","DOIUrl":"10.1016/j.ygyno.2024.10.010","url":null,"abstract":"<p><strong>Background: </strong>Genomic profiling-based model (GP-M) is the gold-standard for endometrial cancer (EC) molecular classification, but several issues related to the availability of genomic sequencing in low-income settings remain and health disparities in the management are increasing. This study aims to investigate the non-inferiority of the immunohistochemistry-alone model in classifying ECs compared to the standard genomic profiling-based model in terms of oncologic outcomes.</p><p><strong>Methods: </strong>All preoperative uterine-confined ECs undergoing surgical staging were retrospectively included. Patients classified by IHC-M were stratified into: MMR-proficient (MMRp), p53 wild type (p53wt) and estrogen receptor (ER) positive, 2) MMRp, p53wt and ER-negative, 3) MMRd, and 4) p53abn. A case-control comparison was performed between the IHC-M and GP-M cohorts. Then, a propensity-matched analysis was performed: ECs classified by IHC-M were matched in a 3:1 ratio with patients classified by GP-M.</p><p><strong>Results: </strong>1587 patients with EC were included. The Kaplan-Meier survival curves for disease-free survival and overall survival demonstrated that the two models performed similarly in risk-stratifying the study population (p < 0.0001). Moreover, the AUC-ROC showed overlapping results: 0.77 (0.66-0.87) for IHC-M and 0.72 (0.63-0.81) for GP-M, indicating that both models were able to successfully identify patients at high-risk and low-risk of disease recurrence/progression.</p><p><strong>Conclusion: </strong>The IHC-M showed overlapping classification performance compared to the GP-M in terms of oncologic outcomes. This study may lay the basis to further investigate the real-life clinical impact of POLE sequencing in molecular classification and the potential stand-alone prognostic role of ER status for further allocation of EC patients into risk classes.</p>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"191 ","pages":"150-157"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma","authors":"Elizabeth G. Thayer,&nbsp;Beryl L. Manning-Geist","doi":"10.1016/j.ygyno.2024.11.008","DOIUrl":"10.1016/j.ygyno.2024.11.008","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"191 ","pages":"Pages A1-A2"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer","authors":"Tong Shu ,&nbsp;Yiming Liang ,&nbsp;Siwen Zhang ,&nbsp;Tianqi Sun ,&nbsp;Yunong Gao ,&nbsp;Chang Guo ,&nbsp;Zhe Li ,&nbsp;Min Gao ,&nbsp;Nan Zhang ,&nbsp;Nan Song ,&nbsp;Naiyi Zhang ,&nbsp;Weijiao Gao ,&nbsp;Wei Wang ,&nbsp;Hongguo Wang ,&nbsp;Yan Cai ,&nbsp;Feng Zhang ,&nbsp;Xuwo Ji ,&nbsp;Yu Dong ,&nbsp;Hong Zheng","doi":"10.1016/j.ygyno.2024.11.002","DOIUrl":"10.1016/j.ygyno.2024.11.002","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to assess the application and effectiveness of tumor-informed Minimal Residual Disease (MRD) detection using circulating tumor DNA (ctDNA) for predicting disease recurrence and survival outcomes in ovarian cancer patients.</div></div><div><h3>Methods</h3><div>Between 2020 and 2022, 31 newly diagnosed stage II-IV ovarian cancer patients were enrolled in this retrospective study. All patients completed standard treatment, including cytoreductive surgery and platinum-based chemotherapy, achieving a complete remission (CR) without receiving first-line PARP inhibitor maintenance therapy. Archived tumor tissue, as well as plasma samples collected pre- and post-treatment, were tested using Whole Exome Sequencing (WES) to identify personalized somatic variants for MRD detection.</div></div><div><h3>Results</h3><div>All pre-treatment (baseline) blood samples showed a 100 % MRD positive rate, demonstrating the high sensitivity of ctDNA-based MRD detection. This rate decreased to 25.8 % in post-treatment (landmark) samples, indicating a significant reduction of ctDNA levels following effective treatment. The median follow-up time until Sep 2023 was 21.4 months, during which 15 patients experienced recurrence. Landmark MRD-positive patients exhibited a markedly shorter median progression-free survival (PFS) compared to MRD-negative patients (5.8 months vs 24.7 months, HR = 6.678, <em>p</em> = 0.01). Furthermore, a strong correlation was observed between post-treatment MRD status and recurrence, with a higher relapse rate in the MRD-positive group.</div></div><div><h3>Conclusion</h3><div>The study establishes MRD detection via ctDNA analysis as a valuable tool for early and accurate prediction of ovarian cancer recurrence, potentially leading to improved clinical outcomes. As a result, integrating MRD detection into routine clinical practice is advocated to enable more effective and personalized treatment strategies for ovarian cancer patients.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages 94-101"},"PeriodicalIF":4.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of neighborhood social vulnerability with ovarian cancer survival","authors":"Lauren Borho ,&nbsp;Esther Elishaev ,&nbsp;Riyue Bao ,&nbsp;Emily O'Brien ,&nbsp;Kaitlyn Dinkins ,&nbsp;Jessica Berger ,&nbsp;Michelle Boisen ,&nbsp;John Comerci ,&nbsp;Madeleine Courtney-Brooks ,&nbsp;Robert P. Edwards ,&nbsp;Alison Aunkst Garrett ,&nbsp;Joseph L. Kelley ,&nbsp;Jamie Lesnock ,&nbsp;Haider S. Mahdi ,&nbsp;Alexander Olawaiye ,&nbsp;Shannon Rush ,&nbsp;Paniti Sukumvanich ,&nbsp;Sarah Taylor ,&nbsp;Ritu Aneja ,&nbsp;Lyse Norian ,&nbsp;Francesmary Modugno","doi":"10.1016/j.ygyno.2024.10.030","DOIUrl":"10.1016/j.ygyno.2024.10.030","url":null,"abstract":"<div><h3>Objective</h3><div>Social determinants of health (<strong>SDOH</strong>) impact cancer outcomes. The CDC Social Vulnerability Index (<strong>SVI</strong>) integrates scores for four neighborhood-based SDOH domains (socioeconomic status, household characteristics, minority status, and housing type/transportation) to assess neighborhood social vulnerability (<strong>NSV)</strong>. While NSV has been associated with overall cancer mortality and lung, breast, colon, and endometrial cancer-specific mortality, the relationship between NSV as defined by the SVI and ovarian cancer outcomes remains unknown.</div></div><div><h3>Methods</h3><div>We used data from 177 patients enrolled in an observational ovarian cancer cohort study from October 2012 through September 2022. All patients underwent debulking surgery and completed an entire course of standard-of-care platinum-based chemotherapy. Follow-up was completed through May 2024. SVI was calculated using census tract at diagnosis. High NSV was defined as SVI in the top quartile of the cohort. Cox proportional hazard models assessed the association between NSV and progression-free (<strong>PFS</strong>) and overall (<strong>OS</strong>) survival.</div></div><div><h3>Results</h3><div>After accounting for demographic and clinical factors, high NSV was associated with significantly worse PFS (HR:2.31 [95% CI:1.48–3.61]; <em>P</em> &lt; 0.001) and OS (HR:1.79 [95% CI:1.10–2.92]; <em>P</em> = 0.02), with neighborhood socioeconomic status associated with significantly worse PFS (HR:2.29 [95% CI:1.47–3.56]; <em>P</em> &lt; 0.001) and OS (HR:1.71 [95% CI:1.04–2.80]; <em>P</em> = 0.03). Neighborhood housing type/transportation was also associated with significantly worse PFS (HR:1.65 [95% CI:1.07–2.55]; <em>P</em> = 0.02) and trended towards worse OS (HR:1.43 [95% CI: 0.80–2.33]).</div></div><div><h3>Conclusion and relevance</h3><div>Higher neighborhood social vulnerability is associated with worse outcomes among ovarian cancer patients. Validating these results in a population-based cohort and assessing programs to reduce neighborhood social vulnerability to improve ovarian cancer outcomes is warranted.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages 32-39"},"PeriodicalIF":4.5,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis","authors":"Giuseppe Marino ,&nbsp;Liliana Marchetta ,&nbsp;Serena Negri ,&nbsp;Filippo Testa ,&nbsp;Daniele Lugotti ,&nbsp;Giulia Cavallo ,&nbsp;Tommaso Grassi ,&nbsp;Marta Jaconi ,&nbsp;Elena De Ponti ,&nbsp;Maria Cristina Bonazzi ,&nbsp;Fabio Landoni ,&nbsp;Robert Fruscio","doi":"10.1016/j.ygyno.2024.11.007","DOIUrl":"10.1016/j.ygyno.2024.11.007","url":null,"abstract":"<div><h3>Background</h3><div>Granulosa cell tumors (GCTs) are rare neoplasia that account for less than 5 % of all the ovarian tumors. Juvenile GCT histotype is generally observed in adolescent and young women, representing a very rare disease, so only a paucity of data are present in literature. The aim of this study is to analyse the oncologic and fertility outcome in our case series of juvenile GCTs.</div></div><div><h3>Methods</h3><div>Clinicopathological data were retrospectively collected and analysed from a cohort of 30 patients ovarian juvenile GCTs treated at IRCCS San Gerardo dei Tintori Hospital, Monza, between 1980 and 2024.</div></div><div><h3>Results</h3><div>The median age of disease onset was 21.5. Among patients enrolled in the study, 80.0 % (24/30) were stage I (16/26, 1/26 and 7/26 of stage IA, IB and IC, respectively), 6.7 % (2/30) were stage II and 13.3 % stage III (4/30). In 86.7 % (26/30) of patients, a fertility-sparing surgery was carried out, while 13.3.% (4/30) of patients underwent radical surgery. Adjuvant chemotherapy was administered in 20.0 % (6/30) of cases, while 80.0 % (24/30) were followed only with surveillance. Three patients in thirty (10.0 %) relapsed and died of disease despite multi-therapeutic approaches. All of them had advanced stages of disease at time of diagnosis.</div></div><div><h3>Conclusions</h3><div>Juvenile GCT appears to have a good prognosis at stage I disease. However, advanced stage represents a hard challenge for clinicians, showing a high rate of relapse and mortality.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages 89-93"},"PeriodicalIF":4.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer","authors":"Andreas Kleppe ,&nbsp;Kristina Lindemann ,&nbsp;Wanja Kildal ,&nbsp;Kari Anne R. Tobin ,&nbsp;Manohar Pradhan ,&nbsp;Ljiljana Vlatkovic ,&nbsp;Maria X. Isaksen ,&nbsp;Håvard E. Danielsen ,&nbsp;Hanne A. Askautrud ,&nbsp;Gunnar B. Kristensen","doi":"10.1016/j.ygyno.2024.11.005","DOIUrl":"10.1016/j.ygyno.2024.11.005","url":null,"abstract":"<div><h3>Introduction</h3><div>The role of molecular classification and L1CAM in high-risk endometrial cancer is uncertain. We aimed to determine the association of molecular profiling and L1CAM with patterns of relapse and survival.</div></div><div><h3>Material and methods</h3><div>This retrospective cohort study included patients referred to Department for Gynecologic Oncology, Oslo University Hospital between January 1, 2006 and December 31, 2017. L1CAM expression and molecular profiling according to ProMisE was performed. Main outcome was time to recurrence (TTR) and cancer specific survival (CSS).</div></div><div><h3>Results</h3><div>Of 489 patients, 486 could be molecular classified. Thirty-seven (8 %) had <em>POLE</em> mutated tumors, 148 (30 %) had MMRd tumors, 189 (39 %) had p53 abnormal tumors, and 112 (23 %) had NSMP tumors. High L1CAM expression was observed in 256 (53 %), low in 227 (46 %) tumors (6 (1 %) missing). ProMisE was significant for TTR but not for CSS in multivariable analysis. L1CAM was significant in multivariable analysis for both TTR and CSS. In a multivariable model with ProMisE and L1CAM expression in the same multivariable model, ProMisE lost significance while L1CAM remained significant. Patients with <em>POLE</em> mutated tumors entailed an excellent prognosis while patients with p53 abnormal or L1CAM overexpressing tumors entailed a poor prognosis with a high frequency of distant recurrences. Patients with MMRd tumors, NSMP and p53 abnormal tumors with low L1CAM had an intermediate prognosis.</div></div><div><h3>Conclusions</h3><div>L1CAM is an additional adverse factor in the p53 abnormal and NSMP groups. These groups need special attention in studies intensifying adjuvant treatment.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"192 ","pages":"Pages 80-88"},"PeriodicalIF":4.5,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}